PolyMedix Receives Patent Related to Its Antibiotic and Antimicrobial Programs.

PHILADELPHIA -- PolyMedix, Inc. (OTC BB: PYMX) announced today that the U.S. Patent and Trademark Office has issued the company U.S. Patent No. 10,471,028 for a patent relating to its antimicrobial compounds. The patent titled, Facially Amphiphilic Polymers as Anti-infective Agents allows compositions of matter and uses for a number of series of antimicrobial compounds for antibiotic and other anti-infective applications.

"This patent represents a significant and strategic accomplishment for PolyMedix. It is the first allowance from our series of applications relating to our antimicrobial program - a program in which we are developing novel antibiotics and antimicrobial biomaterials consisting of small molecule and polymer mimics of the host defense proteins. We remain excited about the advances we are making in this promising program," commented Nicholas Landekic, President and Chief Executive Officer.

About PolyMedix, Inc.

PolyMedix develops acute care products for drug resistant bacteria and acute cardiovascular disorders based on biomimetics - novel non-peptide small molecule drugs that mimic the activity of proteins. PolyMedix's compounds are designed with a proprietary computational drug design technology licensed from the University of Pennsylvania, and are based on the work of Drs. William DeGrado, Michael Klein, and Gregory Tew.

PolyMedix has developed novel small molecule antibiotic drug candidates by mimicking the activity of the host defense proteins, one of the oldest and most effective antimicrobial defense systems present in virtually all living creatures. Unlike many antibiotic drugs which act on biochemical targets and to which bacterial resistance readily develops, PolyMedix's antimicrobial compounds have the potential to be rapid acting broad-spectrum antibiotic drugs because they appear to work biophysically by a novel mechanism that targets and disrupts bacterial cell membranes. These new antibiotics compounds are active against Gram-positive, Gram-negative and drug-resistant bacteria, as well as have antifungal and antiviral properties. Laboratory testing has shown their mechanism of action is associated with a low incidence for the development of resistance.

Drug-resistant bacterial infections are one of the most significant problems facing medicine today. PolyMedix plans to file an IND and start human clinical trials with its first antibiotic drug in 2007.

In acute cardiovascular disorders, the Company is developing an anticoagulant antagonist, a small molecule compound which can reverse the activity of both heparin and low molecular weight heparins. Among other indications, this compound will be developed as a replacement for protamine, currently the only agent approved to reverse heparin activity. PolyMedix hopes that its compound will be safer and easier to use than protamine. Clinical trials are anticipated to begin in 2007.

PolyMedix is also developing polymeric antimicrobial compounds for biomaterials applications, which can be used as additives to paints, plastics, and textiles to create self-sterilizing antimicrobial products and surfaces.

For more information, please visit PolyMedix on its website at www.polymedix.com.

This press release contains forward-looking statements that involve risks and that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission, including those described under the heading "Risk Factors" in the Registration Statement on Form 10-SB originally filed by PolyMedix with the Securities and Exchange Commission on April 5, 2006. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.